Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

・The open-label trial enrolled 90 patients and compared Ratutrelvir with Paxlovid, an oral antiviral medication from Pfizer. ・Early data analysis supports Ratutrelvir’s favorable tolerability profile, ...

Traws Pharma already develops antiviral drugs for influenza, H5N1 bird flu, and COVID-19. ・Hantavirus is a severe rodent-borne disease with a fatality rate of 30% to 50% in humans. ・The World Health ...

Ladies and gentlemen, thank you for standing by. Welcome to the Traws Pharma, Inc. Second Quarter 2025 Financial Results and Business Update Call. [Operator Instructions] As a reminder, this call is ...

Revenue: $2.8 million for the year ended December 31, 2025, compared to $226,000 in 2024. Net Income: $9.2 million for the year ended December 31, 2025, compared to a net loss of $166.5 million in ...

Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies ...

*The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. It is possible that this date will be updated in the future, once the company announces the ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...